Celcuity Inc. (CELC)
CELC Price and Sentiment
CELC Latest news
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
2021-10-18 16:09MINNEAPOLIS--(BUSINESS WIRE)---- $CELC #Celcuity--Celcuity announces clinical trial collaboration with U of Rochester and Puma for Phase 2 breast cancer study. Patient selection guided by CELsignia.
CELC Stock: $50 Price Target From Canaccord
2021-10-11 21:23The shares of Celcuity Inc (NASDAQ: CELC) have received a price target of $50. These are the details.
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-09 16:00Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities After follow-on offering, Celcuity had approximately $94.4 million of cash on hand Expanded clinical development and clinical operations capabilities with appointment of two new senior executives and the addition of other key team members In a Phase 1 study evaluating gedatolisib combined with paclitaxel and carboplatin, 65% of patients (11/17) had an objective response, including three complete responses Management to host webcast and conference call today, August 9, 2021, at 4:30 p.m. ET / 1:30 p.m.
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
2021-08-05 08:00MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present in a virtual fireside chat at 8:30 a.m.
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
2021-08-02 07:30MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the second quarter 2021 after the stock market close on Monday, August 9, 2021. Management will host a teleconference the same day at 4:30 p.m.
Celcuity to Participate in the William Blair Biotech Focus Conference
2021-07-08 16:15MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the William Blair Biotech Focus Conference to be held July 14-15, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity, is scheduled to present in a fireside chat at 2 p.m.
Why Celcuity Stock Is Crashing Today
2021-06-29 11:11The clinical-stage biotech announced the pricing of a secondary stock offering.
Celcuity Announces Pricing of Follow-on Offering
2021-06-28 23:30MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $25.00 per share. As part of the offering, Celcuity has granted the underwriters a 30-day option to purchase up to an additional 337,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
Celcuity Announces Launch of Follow-on Offering
2021-06-28 16:01MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it has commenced an underwritten public offering of shares of its common stock. As part of the offering, Celcuity expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
2021-06-09 09:10MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the addition of two new senior executives to its clinical drug development and operations team. Igor Gorbatchevsky, MD, joined Celcuity as VP of Clinical Development and Jill Krause joined as VP of Clinical Operations.